Tarsons Products Peer Comparison

NSE: TARSONS | BSE: 543399

₹320.95

₹-6.70 (-2.04%)

As on 09-Oct-2026IST

Market cap

₹1,719 Cr

Revenue (TTM)

₹441 Cr

P/E Ratio

154.9

P/B Ratio

2.7

Div. Yield

0 %

Edit

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
Market cap (₹ Cr)	1,719	19	50,528	16,070	7,506
Revenue (₹ Cr)	441	0	6,725	1,997	7,229
Net Profit (₹ Cr)	11.10	-1.61	1,128.79	307.01	210.43
Net Margin (%)	2.37	-431.37	16.02	14.56	2.88
RoE (%)	1.88	-16.73	11.51	10.63	11.02
Price to Earnings	154.94	--	44.76	51.00	35.66
Price-To-Book	2.71	2.34	4.75	5.05	3.75

Income Statement (₹ Cr)

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
Operating Revenue	422.51	0.26	6,430.65	1,875.26	6,892.47
Total Income	447.18	1.04	6,746.98	2,002.19	6,963.79
Total Expenditure	304.87	1.38	4,801.11	1,436.66	6,268.09
EBITDA	117.64	-1.12	1,629.54	438.59	624.38
Depreciation	96.53	0.09	423.67	115.52	282.87
EBIT	21.11	-1.21	1,205.88	323.08	341.51
Interest	22.75	0.24	33.28	21.42	137.50
Other Income	24.67	0.78	316.33	126.93	71.32
Exceptional Items	-1.13	--	-24.35	-6.80	--
Profit before Tax	21.90	-0.68	1,464.58	427.47	275.33
Provision for Tax	7.58	--	437.26	106.74	55.72
Profit after Tax	14.32	-0.68	1,027.32	320.73	219.61

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
Shareholder's Funds	634.69	10.03	10,357.95	3,106.17	1,975.36
Minority Interest	--	--	--	43.07	-0.71
Non-Current Liabilities	286.94	121.32	482.17	120.16	1,225.00
Current Liabilities	264.19	12.74	1,608.40	666.53	763.90
Total Liabilities	1,185.82	144.09	12,448.52	3,951.60	4,084.80

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
Non-Current Assets	920.07	142.83	4,921.74	1,903.19	1,820.29
Current Assets	265.75	1.26	7,526.79	2,032.74	2,143.26
Total Assets	1,185.82	144.09	12,448.52	3,951.60	4,084.80
Total Debt*	382.63	14.52	243.36	341.62	0.00
Net Current Assets	1.56	-11.47	5,918.38	1,366.21	1,379.36
Contingent Liabilities	1.29	2.58	10.12	50.21	14.06

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
Cash From Operating Activities	118.48	1.20	1,031.39	246.37	495.58
Cash Flow from Investing Activities	-130.37	-1.70	137.73	-225.38	-127.72
Cash from Financing Activities	8.93	0.78	-416.97	20.15	-255.51
Net Cash Inflow / Outflow	-2.96	0.28	752.14	41.14	112.36

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
ROCE (%)	4.52	-1.75	14.96	14.05	22.22
ROE (%)	2.26	-6.52	10.56	10.94	11.93
ROA (%)	1.26	-0.47	8.70	8.89	6.00
EBIT Margin (%)	33.68	-129.65	30.26	30.16	10.09
Net Margin (%)	3.20	-64.75	15.23	16.02	3.15
Cash Profit Margin (%)	26.24	-223.59	22.56	23.12	7.19

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
Revenue Growth (%)	7.67	10.98	14.50	12.30	12.33
EBIT Growth (%)	12.19	20.21	31.25	3.80	26.01
Net Profit Growth (%)	-51.89	-3.14	47.07	-5.27	46.18
EPS Growth (%)	-51.89	-3.12	47.07	-4.88	45.68
Book Value Growth (%)	0.71	-6.38	12.70	12.14	14.76

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
Price / Earnings	61.95	0.00	27.22	37.47	45.79
Price / Book Value	1.40	2.53	2.71	3.90	5.11
Dividend Yield (%)	0.00	0.00	1.18	0.29	0.00
EV/EBITDA	8.75	-117.21	12.77	21.79	13.79
Market Cap (₹ Cr)	887.19	25.38	27,964.97	12,069.92	10,057.49

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
Debt to Equity	0.60	1.45	0.02	0.11	0.00
Short term debt to equity ratio	0.14	0.84	--	0.08	--
Current Ratio	1.01	0.10	4.68	3.05	2.81
Quick Ratio	0.51	0.10	3.60	2.40	1.00
Interest Coverage	1.96	-1.76	45.01	20.96	3.00

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
Debtors to sales (%)	20.21	3.22	29.41	28.33	0.39
Asset Turnover	0.37	0.00	0.54	0.52	1.91
Receivable days	71.27	11.76	96.72	85.20	1.05
Inventory Days	110.50	47.53	97.32	69.58	71.25
Payable days	47.34	--	134.60	77.97	21.75
Cash Conversion Cycle	134.44	--	59.43	76.82	50.55

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.